UCL Institute of Neurology
- IoN HOME
- About the Institute
- Study Here
- Research Departments
- Research Groups and Themes A-Z
- Department of Brain Repair & Rehabilitation
- Department of Clinical and Experimental Epilepsy
- Department of Clinical Neuroscience
- Department of Molecular Neuroscience
- Department of Neurodegenerative Disease
- Department of Neuroinflammation
- Sobell Department of Motor Neuroscience and Movement Disorders
- Wellcome Trust Centre for Neuroimaging
- Clinical Divisions
- Athena SWAN
- Services & Library
- Vacancies and PhDs
- National Hospital for Neurology and Neurosurgery
- Support the Institute and National Hospital
- Contact Us
UCL awarded £13.5 million to advance medical research facilities
Publication date: 23 October 2014
As part of the Clinical Research Infrastructure Initiative, UCL has been awarded £13.5 million for a number of projects to help advance clinical research.
Toxic proteins implicated in frontotemporal dementia and motor neurone disease
Publication date: 11 August 2014
Professor Tabrizi and Professor Price elected to Fellowship of the Academy of Medical Sciences.
Publication date: 12 May 2014
Professor Sarah Tabrizi (Department of Neurodegenerative Diseases, UCL Institute of Neurology and
Honorary Consultant Neurologist at the National Hospital of Neurology and
Neurosurgery) and Professor Cathy Price (Wellcome Trust Centre for Neuroimaging, UCL Institute of Neurology) have been recognised for their contribution to the advancement of medical science by election to the Fellowship of the Academy of Medical Sciences.
Population Screening for vCJD Using a Novel Blood Test
Publication date: 7 March 2014
There are real concerns
over the number of people in the UK that, although well, maybe infected with Variant Creutzfeldt-Jakob Disease (vCJD),
the human form of mad cow disease.
Chief Medical Officer appoints Professor Rossor as NIHR National Director for Dementia Research
Publication date: 4 March 2014
Lowering levels of toxic protein reverses abnormalities in cells from patients with Huntington's disease
Publication date: 24 January 2014
scientists, led by Professor Sarah Tabrizi at the UCL Institute
of Neurology, in collaboration with colleagues at the University of Massachusetts
Medical School, have shown for the first time that switching off the mutant
protein that causes the fatal brain disorder Huntington’s disease can reverse
abnormalities in living cells taken from patients with the disease.
UCL takes the lead with £8.5m funding for dementia research
Publication date: 11 December 2013
UCL has been awarded more than £8.5 million by the Economic and Social Research Council (ESRC) and the National Institute for Health Research (NIHR) to help tackle the challenges associated with dementia.
Secretary of State visits leading dementia research projects
Publication date: 11 December 2013
The Prime Minister today called for a global effort to tackle one of the greatest challenges of our time: dementia. UCL scientists, working with clinicians at the university's partner hospitals, are at the heart of the battle to treat the condition.
New £20m centre pioneers first-in-man trials for neurodegenerative diseases
Publication date: 15 November 2013
A specialist £20 million research centre, funded by the Wolfson Foundation and dedicated to carrying out first-in-human studies, opens in London today. Researchers at the Leonard Wolfson Experimental Neurology Centre (LWENC) will investigate exciting new therapies for neurodegenerative diseases such as Alzheimer’s and Parkinson’s.
RNA build-up linked to dementia and motor neuron disease
Publication date: 4 November 2013
A new toxic entity associated with genetically inherited forms of dementia and motor neuron disease has been identified by scientists at the UCL Institute of Neurology. The toxin is the result of a genetic mutation that leads to the production of RNA molecules which could be responsible for the diseases. The findings are published in the journal Acta Neuropathologica.
Researchers estimate one in 2,000 people in the UK carry variant CJD proteins
Publication date: 16 October 2013
A study led by Sebastian Brandner at the Department of Neurodegenerative disease, UCL Institute of Neurology, in collaboration with the AHVLA in Weybridge and Public Health England shows all ages and genotypes to be affected.
Scientists develop refined diagnostic tool for inherited dementias
Publication date: 19 September 2013
Researchers at the MRC Prion Unit and the NIHR Queen Square Dementia Biomedical Research Unit (BRU) have developed and tested an integrated tool (the ‘MRC Dementia Gene Panel’) to diagnose early onset, genetic forms of dementia, bringing together for the first time all 17 genes known to play a substantial role in causing inherited forms of dementia.
TRACK-HD study identifies early predictors of disease progression in Huntington’s disease
Publication date: 9 May 2013
An international team led by researchers at the UCL Institute of Neurology has identified a set of tests that could help identify whether - and how - Huntington’s disease (HD) is progressing in groups of people who are not yet showing symptoms.
UCL Institute of Neurology enters gene-editing research collaboration with Horizon Discovery
Publication date: 12 November 2012
Professor Sarah Tabrizi, UCL Institute of Neurology and principal investigator of the TRACK-HD study, discusses a new research partnership between the Institute and Horizon Discovery, a technology company that provides researchers with tools to support translational genomics research. Read more: Genetic Engineering and Biotechnology News
Toxic protein build-up in blood shines light on fatal brain disease
Publication date: 24 September 2012
A new light-based technique for measuring levels of the toxic protein that causes Huntington’s disease (HD) has been used to demonstrate that the protein builds up gradually in blood cells. Published today (17th) in the Journal of Clinical Investigation, the findings shed light on how the protein causes damage in the brain, and could be useful for monitoring the progression of HD, or testing new drugs aimed at suppressing production of the harmful protein.
Unlocking the mysteries of the mind
Publication date: 1 June 2012
Like cancer and HIV decades before, the solution to stopping dementia in its tracks has remained stubbornly intransigent. But there is hope.
The race to find a cure for dementia has never been more critical: within ten years there will be around one million people in the UK with this devastating condition – many of whom will spend their last few years severely impaired and dependent on others for care.
The NHNN and UCL Institute of Neurology are at the research epicentre and have recently been awarded grants totaling over £30 million.
International project to determine vascular contribution to neurodegeneration begins
Publication date: 19 April 2012
18 April 2012
Congratulations to UCL Institute of Neurology scientists, Dr David Werring and Professor Nick Fox, who are part of an international team of scientists that has recently been awarded funding from the Centres of Excellence in Neurodegeneration (CoEN) to study how vascular disease contributes to neurodegenerative disease. The project, titled Standards for Determining the Vascular Contribution to Neurodegeneration, aims to create a common, albeit expert set of definitions and terminology to describe neuroimaging findings related to diseases affecting brain small vessels. These diseases, including hypertensive arteriopathy and cerebral amyloid angiopathy, are among the commonest to affect the brain and are key causes of stroke and dementia.
Prime Minister visits UCL Institute of Neurology
Publication date: 27 March 2012
Wolfson Foundation awards £20million to UCL for experimental neurology centre
Publication date: 19 December 2011
A new centre dedicated to the understanding and treatment of neurodegenerative diseases will be established at UCL following the award of a £20million grant from the Wolfson Foundation, it was announced today.
Researchers move closer to finding successful drugs to treat Huntington’s disease
Publication date: 8 December 2011
Source: The Lancet/The Lancet Neurology Press Release
TRACK-HD investigators, including UCL Institute of Neurology researchers have identified a set of objective, validated measures that can be used to assess new treatments for Huntington’s disease (HD). The study, published last week in The Lancet Neurology, should increase the likelihood of success of future trials of new drugs to delay the onset and reduce the severity of HD.
UCL scientists get £88k boost to study hearing problems in Alzheimer’s
Publication date: 25 November 2011
Source: Alzheimer’s Research UK Press Release
UCL Institute of Neurology PhD student, Hannah Golden, is embarking on a project to understand the causes of hearing problems in Alzheimer’s disease, thanks to an £88,000 grant from Alzheimer’s Research UK, the UK’s leading dementia research charity. It’s hoped the study, which is the one of the first of its kind, could improve diagnosis and lead to new ways of helping patients cope with their symptoms.
Neurodegenerative disease research projects secure international collaborative funding
Publication date: 8 September 2011
Congratulations to UCL Institute of Neurology professor’s Martin Rossor and Anthony Schapira, who have both been awarded funding in the first ever Centres of Excellence in Neurodegeneration Research (CoEN) initiative. CoEN, an international collaborative of research funders including UK’s Medical Research Council, launched the initiative last year, with a remit of bringing together researchers from labs across the globe to further our understanding of neurodegenerative diseases and identify new ways of treating these diseases.
UCL Alzheimer’s researcher receives lifetime achievement award
Publication date: 18 July 2011
Dr Jonathan Schott receives the US Alzheimer Association 2011 de Leon Prize in Neuroimaging: New Investigator Award
Publication date: 14 July 2011
Study reveals genetic clues underlying progressive supranuclear palsy
Publication date: 20 June 2011
Scientists are one step closer to understanding the genes associated with the rare neurodegenerative disease, progressive supranuclear palsy (PSP), according to a study published in the current Nature Genetics. The genomewide association study was completed by an international consortium of researchers, including members of UCL Institute of Neurology’s Reta Lila Weston Institute (RLWI).